Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2001

View Archived Issues

Candidate mucin production inhibitor presented at ATS 2001

Long-term efficacy and safety data for adalimumab discussed at EULAR 2001

Third phase II trial of LDP-341 begins

Pharming's rhC1 inhibitor granted orphan drug designation from EMEA

InterMune licenses Infergen from Amgen

Anakinra can arrest joint destruction in active rheumatoid arthritis

MIF antagonists and their potential therapeutic application patented by PIMR researchers

Worldwide clinical development program for Generx to be launched

Kaken presents new compounds acting as VLA-4 antagonists

New MMP and TNF-alpha production inhibitors designed by Ajinomoto scientists

Succinic acid derivatives useful for potentiating activity of beta-lactam antibiotics

Naturally produced antiproliferative compounds discovered by CNRS team

Pyrazolone-based kinase inhibitors reported in recent patent by Cephalon

Exploratory trial of IC-351 in female sexual arousal disorder shows no conclusive treatment effect

Milkhaus expands clinical testing of BPH agent

PEG sTNF-RI produces significant improvement in signs, symptoms and HRQOL in RA patients

ImClone reaches second milestone in phase III evaluation of BEC2

Metvix PDT receives first approval in Sweden

Recombinant urate oxidase now available for acute tumor lysis syndrome

Cardioprotective properties demonstrated for LU-135252 in infarcted SHSRP

Novartis seeks E.U. approval of Elidel atopic dermatitis treatment

Receptor subtype-selective muscarinic agonist compares favorably with pilocarpine in primates

Solvay commences Canadian study of Teveten in combination with home blood pressure monitoring

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...